Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-costunolide
0.5 mM, 30°C, pH 6.8, 56.5% inhibition
(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)(methoxymethanolato-kappaO)zinc
-
-
(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)(nitrato-kappaO)copper
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
0.5 mM, 30°C, pH 6.8, 81.5% inhibition
(2S)-2-(dimethylamino)-3-(ethylthio)propan-1-ol
(2S)-2-(dimethylamino)-3-ethoxypropane-1-thiol
(2S)-2-(dimethylamino)-3-mercaptopropan-1-ol
(2S)-2-(dimethylamino)-3-methoxypropane-1-thiol
(aminomethyl)methylphosphinic acid
-
-
(aminomethyl)phosphonic acid
(E)-1-((E)-3-phenylallylidene)thiosemicarbazide
-
-
(E)-1-(2-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(3,4,5-trimethoxybenzylidene)thiosemicarbazide
-
-
(E)-1-(3-bromobenzylidene)thiosemicarbazide
-
-
(E)-1-(3-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(3-methoxybenzylidene)thiosemicarbazide
-
-
(E)-1-(3-nitrobenzylidene)thiosemicarbazide
-
competitive mechanism of inhibition
(E)-1-(4-(N,N-dimethylamino)benzylidene)thiosemicarbazide
-
-
(E)-1-(4-bromobenzylidene)thiosemicarbazide
-
-
(E)-1-(4-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(4-methoxybenzylidene)thiosemicarbazide
-
-
(E)-1-(4-nitrobenzylidene)thiosemicarbazide
-
-
(E)-2-((E)-but-2-enylidene)hydrazinecarbothioamide
-
-
(E)-2-(2,3-dihydroxybenzylidene)hydrazinecarbothioamide
-
-
(E)-2-(2-(benzyloxy)benzylidene)hydrazinecarbothioamide
-
-
(E)-2-(3-(benzyloxy)-4-methoxybenzylidene)hydrazinecarbothioamide
-
-
(E)-2-(4-hydroxy-3,5-dimethoxybenzylidene)hydrazinecarbothioamide
-
-
(E)-2-(4-hydroxybenzylidene)hydrazinecarbothioamide
-
-
([[(benzyloxy)carbonyl]amino]methyl)methylphosphinothioic O-acid
1'-(trifluoroacetyl)-1,4'-bipiperidine
-
50% inhibition at 0.061 mM
1,1-dimethyl-3-[(1S)-1-naphthalen-1-ylethyl]selenourea
-
-
1,10-phenanthroline
-
5 mM, 67% inhibition
1,3-bis(3-chlorophenyl)thiourea
-
-
1-(2,4-difluorophenyl)-3-phenylthiourea
-
-
1-(2,4-dihydroxyphenyl)-2-(4-fluorophenyl)ethanone oxime
-
-
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone
-
0.4 mg/ml, 16% inhibition
1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone oxime
-
-
1-(2,5-dimethoxyphenyl)-3-phenylthiourea
-
-
1-(2-chlorophenyl)-3-(3-chlorophenyl)thiourea
-
-
1-(2-chloropyridin-3-yl)-3-phenylthiourea
-
-
1-(2-hydroxy-4,6-dimethoxyphenyl)-2-(4-methoxyphenyl)ethanone oxime
-
-
1-(3,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone
-
0.4 mg/ml, 39% inhibition
1-(3,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone oxime
-
-
1-(3,5-dichloropyridin-2-yl)-3-phenylthiourea
-
-
1-(3-bromophenyl)-3-phenylthiourea
-
-
1-(3-chlorophenyl)-3-(2,3-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,4-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,4-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,5-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,6-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,6-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2-chloropyridin-3-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(2-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3,4-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3,4-difluorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3-methylpyridin-2-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-chlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-fluorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(m-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(o-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(p-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-3-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-3-ylmethyl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-4-ylmethyl)thiourea
-
-
1-(3-methylpyridin-2-yl)-3-phenylthiourea
-
-
1-(4-bromophenyl)-3-phenylthiourea
-
-
1-(5-bromo-6-methylpyridin-2-yl)-3-phenylthiourea
-
-
1-(5-chloro-2-methylphenyl)-3-(3-chlorophenyl)thiourea
-
-
1-(furan-2-ylmethyl)-3-phenylthiourea
-
-
1-benzyl-2-ethyl-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-benzyl-2-ethyl-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-cyclohexyl-3,3-dimethyl-1-(1-methylethyl)selenourea
-
-
1-ethoxy-2-ethyl-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-ethoxy-2-ethyl-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-phenyl-3-(pyridin-2-yl)thiourea
-
-
1-phenyl-3-(pyridin-3-yl)thiourea
-
-
1-phenyl-3-(pyridin-3-ylmethyl)thiourea
-
-
1-phenyl-3-(pyridin-4-yl)thiourea
-
-
1-phenyl-3-(pyridin-4-ylmethyl)thiourea
-
-
10-hydroxyaloin A
0.5 mM, 30°C, pH 6.8, 46.9% inhibition
12-hydroxytetradecanoic acid
-
48.47% inhibition at 100 ng/ml
2',4',5',7-tetramethoxyisoflavone
-
-
2,2'-bi-1,3,4-oxadiazole-5,5'(4H,4'H)-dithione
2,2'-bi-1,3,4-thiadiazole-5,5'(4H,4'H)-dithione
2,2'-thenoin
-
IC50: 0.18 mM
2,3,4,4'-tetrahydroxydeoxybenzoin
-
0.4 mg/ml, 51% inhibition
2,3,4-trihydroxy-4'-methoxydeoxybenzoin
-
0.4 mg/ml, 44% inhibition
2,3-dichloro-N'-(2,3-dichlorobenzoyl)benzohydrazide
-
2,3-dichloro-N'-(3,5-dichlorobenzoyl)benzohydrazide
-
2,3-dichloro-N'-(3,5-dimethylbenzoyl)benzohydrazide
-
2,3-dichloro-N'-(3-chlorobenzoyl)benzohydrazide
-
2,4,4',6-tetrahydroxy-3-methoxyphenyldeoxybenzoin
-
0.4 mg/ml, 17% inhibition
2,4,6-trihydroxy-9H-xanthen-9-one
-
-
2,4,6-trimethyl-N-([1-[(2,4,6-trimethylphenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.038 mM
2,4-dichloro-N'-(2,4-dichlorobenzoyl)benzohydrazide
-
2,4-dichloro-N'-(3,5-dichlorobenzoyl)benzohydrazide
-
2,4-dihydroxy-4'-methoxydeoxybenzoin
-
0.4 mg/ml, 14% inhibition
2,4-dihydroxyacetophenone
-
0.4 mg/ml, 14% inhibition
2,4-diphenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-(1-amino-2-(4-hydroxyphenyl)ethyl)-4-methoxybenzene-1,3,5-triol
-
-
2-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,3,5-triol
-
-
2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,3,4-trihydroxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,4,6-trihydroxy-3-methoxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone oxime
-
-
2-(4-methoxyphenyl)-1-(2,3,4-trimethoxyphenyl)ethanamine
-
-
2-(4-methylphenyl)-4-phenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-(4-nitrophenyl)-4-phenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-chloro-N'-(3-chlorobenzoyl)-4-methylbenzohydrazide
-
2-ethyl-1-(2-phenylethyl)-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-1-(4-methoxycyclohexyl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-1-(4-methoxyphenyl)-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-6-[2-(ethylsulfanyl)propyl]-1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-hydroxy-1-phenylethanone
-
IC50: 0.47 mM
2-iodo-N'-(3-methylbenzoyl)benzohydrazide
-
2-thioxo-5-(2,3,4-trihydroxybenzylidene)dihydro-4,6(1H,5H)-pyrimidinedione
-
-
2-[(1E)-N-(allyloxy)butanimidoyl]-5,5-dimethylcyclohexane-1,3-dione
-
chelator of the nickel atom in enzyme metallocenter
2-[(1E)-N-ethoxybutanimidoyl]-5,5-dimethylcyclohexane-1,3-dione
-
chelator of the nickel atom in enzyme metallocenter
2-[(2S,4R)-2-(4-fluorophenyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[(2S,4R)-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[2-(1,3-benzodioxol-5-yl)-2,3-dihydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[2-(3,4-dimethoxyphenyl)ethyl]phenol
-
-
2-[4-(2-methylpropyl)phenyl]-N-[(2,4,6-trimethylphenyl)carbamothioyl]propanamide
-
2-[4-(2-methylpropyl)phenyl]-N-[(3-nitrophenyl)carbamothioyl]propanamide
-
2-[4-(2-methylpropyl)phenyl]-N-[(4-sulfamoylphenyl)carbamothioyl]propanamide
-
3,3'-(1H-indol-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(1H-pyrrol-2-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(2-bromobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-chlorobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-phenylpropane-1,1-diyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(2-phenylpropylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-pyridyl-methylene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-pyrolidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2E)-but-2-ene-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(3-chlorobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-cinnamylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-hydroxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-indolidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-phenylpropane-1,1-diyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(4-hydroxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(4-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(4-nitrobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(crotonalidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(dihydrocinnamylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(naphthalen-1-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(pyridin-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(pyridin-4-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-butane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-ethane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-ethylidenebis-(4-hydroxycoumarin)
-
-
3,3'-hexane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methylenebis-(4-hydroxycoumarin)
-
-
3,3'-n-butylidene-bis(4-hydroxycoumarin)
-
-
3,3'-n-hexylidene-bis(4-hydroxycoumarin)
-
-
3,3'-n-pentylidene-bis(4-hydroxycoumarin)
-
-
3,3'-pentane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(1E)-1-phenylprop-1-ene-3,3-diyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-bromophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-chlorophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3,4,5-trimethoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3,4-dimethoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-aminophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-chlorophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-ethoxy-4-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-nitrophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-nitrophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(1-methylethyl)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(dimethylamino)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,4,5-trihydroxy-9H-xanthen-9-one
-
-
3,4-Dihydroxyacetophenone
-
0.4 mg/ml, 41% inhibition
3,5-dichloro-N'-(3-chlorobenzoyl)benzohydrazide
-
3,5-dichloro-N'-(3-methylbenzoyl)benzohydrazide
-
3,5-dichloro-N'-(4-chlorobenzoyl)benzohydrazide
-
3,5-dichloro-N'-(4-methoxybenzoyl)benzohydrazide
-
3,5-dichloro-N'-(4-methylbenzoyl)benzohydrazide
-
3,5-dimethylphenyl diamidophosphate
-
-
3-(4-bromobenzyl)-1,1-dimethylselenourea
-
-
3-(4-bromophenyl)-1,1-dimethylthiourea
-
-
3-chloro-N'-(3-chlorobenzoyl)benzohydrazide
-
3-chloro-N'-(3-methylbenzoyl)benzohydrazide
-
3-chloro-N'-(3-nitrobenzoyl)benzohydrazide
-
3-chloro-N'-(4-methylbenzoyl)benzohydrazide
-
3-dodecyl-1,1-dimethylthiourea
-
-
3-hydroxytetradecanoic acid
-
49.20% inhibition at 100 ng/ml
3-methyl-N'-(3-methylbenzoyl)benzohydrazide
-
3-methyl-N-[[1-(3-methylbut-2-en-1-yl)piperidin-4-yl]methyl]but-2-en-1-amine
-
50% inhibition at 0.063 mM
3-phenoxy-N-[[1-(3-phenoxypropyl)piperidin-4-yl]methyl]propan-1-amine
-
50% inhibition at 0.043 mM
3-[(2-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
54% inhibition at 0.01 mM
3-[(2-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
44% inhibition at 0.01 mM
3-[(3-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
28% inhibition at 0.01 mM
3-[(3-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
3% inhibition at 0.01 mM
3-[(4-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
5% inhibition at 0.01 mM
3-[(4-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
21% inhibition at 0.01 mM
3-[(4-[[5-(2-bromophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(3-bromophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(4-[[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]-4-hydroxy-2H-1-benzopyran-2-one
-
3-[(mesitylamino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
4'-O-methylalpinumisoflavone
-
-
4-(1-amino-2-(4-fluorophenyl)ethyl)benzene-1,2,3-triol
-
-
-
4-(1-amino-2-(4-fluorophenyl)ethyl)benzene-1,3-diol
-
-
4-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,2,3-triol
-
-
4-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,2-diol
-
-
4-(1-amino-2-(4-methoxyphenyl)ethyl)benzene-1,3-diol
-
-
4-(2,3-dimethylphenyl)-5-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(2,4-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(2,4-difluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(2,4-dimethylphenyl)-5-(3-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(2,5-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-difluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-dimethoxyphenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3-aminophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-benzoyl-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)phenyl benzoate
4-(4-bromophenyl)-5-[hydroxy(phenyl)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(4-bromophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-chlorophenyl)-5-[hydroxy(phenyl)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(4-chlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-fluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-methoxyphenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(2,4,6-trimethoxyphenyl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(4-nitrophenyl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(pyridin-2-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(thiophen-2-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-phenylpyrimidin-2-amine
-
-
4-(benzyloxy)phenyl diamidophosphate
-
-
4-(methoxymethyl)-5-methylbenzene-1,3-diol
0.5 mM, 30°C, pH 6.8, 91.5% inhibition
4-(p-hydroxyphenethyl)pyrogallol
-
0.4 mg/ml, 94.5% inhibition
4-amino-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
4-amino-5-pyridin-4-yl-2,4-dihydro-3H-1,2,4-triazole-3-thione
4-bromo-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
23% inhibition at 0.01 mM
4-bromophenylboronic acid
4-butylbenzene-1,2,3-triol
-
-
4-butylbenzene-1,2-diol
-
-
4-chloro-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
14% inhibition at 0.01 mM
4-decylbenzene-1,2,3-triol
-
-
4-dodecylbenzene-1,2,3-triol
-
-
4-ethylbenzene-1,2,3-triol
-
-
4-ethylbenzene-1,2-diol
-
-
4-hexylbenzene-1,2,3-triol
-
-
4-hexylbenzene-1,2-diol
-
-
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)-3-phenylprop-2-en-1-yl]-2H-chromen-2-one
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)but-2-en-1-yl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(2-methylphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(3-methoxyphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(3-methylphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(3-nitrophenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)(4-[[5-(4-methylphenyl)-1,3,4-thiadiazol-2-yl]amino]phenyl)methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)[4-([5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]amino)phenyl]methyl]-2H-1-benzopyran-2-one
-
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-indol-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-pyrrol-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(3-methoxyphenyl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(pyridin-4-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)ethyl]-2H-chromen-2-one
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)pentyl]-2H-chromen-2-one
4-hydroxy-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
22% inhibition at 0.01 mM
4-methyl-N-([1-[(4-methylphenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.042 mM
4-nitro-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl] benzohydrazide
60% inhibition at 0.01 mM
4-nitro-N-([1-[(4-nitrophenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.032 mM
4-nitrophenyl diamidophosphate
-
-
4-octylbenzene-1,2,3-triol
-
-
4-octylbenzene-1,2-diol
-
-
4-tetradecylbenzene-1,2,3-triol
-
-
4-[2-(3,4-diethoxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]phenol
-
-
4-[2-(3-bromophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3-bromophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(3-chlorophenyl)ethyl]-1,2-dimethoxybenzene
-
-
4-[2-(3-chlorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3-chlorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-bromophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-chlorophenyl)ethyl]-1,2-dimethoxybenzene
-
-
4-[2-(4-chlorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-chlorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-fluorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-fluorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-hydroxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-hydroxyphenyl)ethyl]benzene-1,2-diol
-
-
5-(1,4-dihydro-9-anthracenylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(1-naphthyl)-1,3,4-oxadiazole-2(3H)-thione
5-(1H-indol-3-ylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2,4-dihydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-aminobenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-bromo-4,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-chlorophenyl)-N-(2,6-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(2-hydroxy-3-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-hydroxy-5-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-methylbenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-thienylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,4-dihydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,4-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,5-dibromo-4-hydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,5-dichloro-2-hydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3-chlorophenyl)-4-(2,4-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(3-chlorophenyl)-4-(2,6-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(3-hydroxy-4-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
5-(4-bromo-2,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-chlorophenyl)-4-(2,4-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(4-chlorophenyl)-N-(2,3-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(4-chlorophenyl)-N-(2,6-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(4-ethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-hydroxy-3,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-hydroxy-3-iodo-5-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H) pyrimidinedione
-
-
5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
5-(4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione
-
-
5-(4-propoxyphenyl)-3-propyl-1,3,4-thiadiazole-2(3H)-thione
-
-
5-(4-pyridinylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-[[4,6-dioxo-2-thioxotetrahydro-5(2H)pyrimidinylidene]methyl]-benzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
5-benzyl-1,3,4-oxadiazole-2(3H)-thione
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
5-fluorouridine
-
the combination of 0.3 mM zeatin with the protein inhibitor results in the alleviation of their inhibitory effect on the urease activity
5-hydroxy-1,4-naphthoquinone
-
5-hydroxy-1,4-naphthoquinone, juglone, acts as a strong, time and concentration dependent inactivator of urease. The reactivation of juglone-modified urease shows the participation of reversible and irreversible contribution in the inactivation. In the presence of an excess of DTT, urease inactivated by juglone regains 70% of its activity. The reversible inactivation is attributed to oxidation of the essential urease thiols by reactive oxygen species (ROS) realizing during reduction of juglone to seminaphthoquinone. The irreversible contribution in the inhibition is assumed as an arylation of urease thiol groups by juglone
5-phenyl-1,3,4-oxadiazole-2(3H)-thione
5-phenyl-1,3,4-thiadiazole-2(3H)-thione
5-pyridin-4-yl-1,3,4-oxadiazole-2(3H)-thione
5-pyridin-4-yl-1,3,4-thiadiazole-2(3H)-thione
5-[(2-hydroxy-1-naphthyl)methylene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[(5-methyl-2-furyl)methylene]-2-thioxodihydro-4,6(1H,5H)pyrimidinedione
-
-
5-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione
5-[(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)methyl]-1,3,4-thiadiazole-2(3H)-thione
5-[(6-bromo-4-chloro-2-oxo-2H-chromen-3-yl)methylene]-2-thioxodihydro 4,6(1H,5H)-pyrimidinedione
-
-
5-[(6-methyl-2-pyridinyl)methylene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[3-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl]-1,3,4-oxadiazole-2(3H)-thione
5-[3-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4(dimethylamino) benzylidene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
5-[4-(methylsulfanyl)benzylidene]-2-thioxodihydro-4,6(1H,5H) pyrimidinedione
-
-
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]oxadiazole-2-thione
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]thiadiazole-2-thione
-
-
5-[hydroxy(phenyl)methyl]-4-(4-methylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-[hydroxy(phenyl)methyl]-4-(4-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
6'-O-coumaroylaloesin
0.5 mM, 30°C, pH 6.8, 91.3% inhibition
6-(1-hydroxy-2-(4-methoxyphenyl)ethyl)-2,3-dimethoxyphenol
-
0.4 mg/ml, 42% inhibition
6-hydroxytetradecanoic acid
-
59.01% inhibition at 100 ng/ml
6a,12a-dehydroxydegueline
-
-
7'-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7-yl alpha-L-mannopyranoside
7'-hydroxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
7'-methoxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
7,8,4'-trihydroxyisoflavone
-
0.4 mg/ml, 81.7% inhibition
7-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7'-yl alpha-L-mannopyranoside
7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
-
-
7-hydroxy-4-methoxy-5-methyl-2H-1-benzopyran-2-one
-
7-hydroxytetradecanoic acid
-
53.43% inhibition at 100 ng/ml
7-methoxy-6'-O-coumaroylaloesin
0.5 mM, 30°C, pH 6.8, 93.5% inhibition
7-[(7-methoxy-2-oxo-2H-chromen-3-yl)oxy]-2-oxo-2H-chromen-6-yl alpha-D-glucopyranoside
8-hydroxy-3-[(6-hydroxy-2-oxo-2H-chromen-7-yl)oxy]-2-oxo-2H-chromen-7-yl beta-D-glucopyranoside
8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4(3H)-dione
26% inhibition at 0.01 mM
8-methyl-3-[(2-sulfanylanilino)methylidene]-2H-pyrido[1,2-a]pyrimidine-2,4-dione
73% inhibition at 0.01 mM
8-methyl-3-[[(4-methyl-2-pyridinyl)amino]methylidene]-2Hpyrido[1,2-]pyrimidine-2,4-dione
20% inhibition at 0.01 mM
8-methyl-3-[[(5-methyl-2-pyridinyl)amino] methylidene]-2H-pyrido[1,2-]pyrimidine-2,4-dione
48% inhibition at 0.01 mM
8-methyl-3-[[(5-nitro-2-pyridinyl)amino] methylidene]-2H-pyrido[1,2-a]pyrimidine-2,4-dione
36% inhibition at 0.01 mM
9-hydroxytetradecanoic acid
-
52.97% inhibition at 100 ng/ml
Allicin
-
from garlic, inhibits the biofilm formation and urease activity in vitro in both prelysed and intact cells. A higher concentration of allicin is needed to inhibit the established biofilms
aloe emodin
0.5 mM, 30°C, pH 6.8, 83.5% inhibition
aloe emodin 11-O-alpha-D-rhamnopyranoside
0.5 mM, 30°C, pH 6.8, 53.6% inhibition
aloinoside B
0.5 mM, 30°C, pH 6.8, 45.7% inhibition
alpha-Amanitin
-
the combination of 0.3 mM zeatin with the protein inhibitor results in the alleviation of their inhibitory effect on the urease activity
aminomethyl(P-methyl)phosphinic acid
beta-(o-methoxyphenyl)-gamma,gamma-bis(8-quinolinoxy)germa-gamma-lactone
-
inhibition occurrs in a noncompetitive and concentration-dependent manner. Highly selective in inhibiting the growth of Proteus mirabilis at moderate concentrations. Potential to be developed as antimicrobial agents against Proteus mirabilis infection
beta-(o-methylphenyl)-gamma,gamma-bis(8-quinolinoxy)germa-gamma-lactone
-
inhibition occurrs in a noncompetitive and concentration-dependent manner. Highly selective in inhibiting the growth of Proteus mirabilis at moderate concentrations. Potential to be developed as antimicrobial agents against Proteus mirabilis infection
Calopogonium isoflavone A
-
-
chloro(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)copper
-
-
citrate
binding of the ligand to the active site involves stabilizing interactions, such as a carboxylate group that binds the nickel ions at the active site and several hydrogen bonds with the surrounding residues
copper(II) complex [CuClL1]*CH3OH
-
L2 is the deprotonated form of 4-bromo-N'-(2-hydroxy-5-methoxybenzylidene)benzohydrazide
copper(II) complex [CuClL2]*CH3OH
-
L3 is the deprotonated form of N'-(2-hydroxy-5-methoxybenzylidene)-3-methylbenzohydrazide
copper(II) complex [CuL1(NCS)]
-
L1 is the deprotonated form of N'-(2-hydroxybenzylidene)-3-methylbenzohydrazide. NCS is N-chlorsuccinimide
copper(II) complex [CuL3(NCS)]*CH3OH
-
L4 is the deprotonated form of 2-chloro-N'-(2-hydroxy-5-methoxybenzylidene)benzohydrazide
copper(II) complex [CuL4(NCS)]*0.4H2O
-
L5 is the dianionic form of N'-(2-hydroxybenzylidene)-3-methylbenzohydrazide
copper(II) complex [CuL5(bipy)]
-
bipy is 2,2'-bipyridine
cordycepin
-
the combination of 0.3 mM zeatin with the protein inhibitor results in the alleviation of their inhibitory effect on the urease activity
cyanide
-
1.0 mM, 32% inhibition
dehydroascorbic acid
-
inhibitory action of dehydroascorbic acid is revealed in the presence of Fe3+ ions and found to be primarily mediated by H2O2. The resulting inhibition by dehydroascorbic acid -Fe3+ consists of enzyme thiol oxidation and its effectiveness grew with increasing pH
emodin
0.5 mM, 30°C, pH 6.8, 46.9% inhibition
epigallocatechin
strong time-dependent inactivation of urease that is not due to their oxygen sensitivity. Rather, the compound appears to inactivate urease by reacting with a specific Cys residue located on the flexible loop. Substitution of this cysteine by alanine in the C319A variant increases the urease resistance
ethanol
50% inhibition at 30% v/v
ethyl 4-(3-benzoylthioureido) benzoate
-
ethyl 4-[3-(2,4-dichlorobenzoyl)thioureido]benzoate
-
ethyl 4-[3-(2-bromobenzoyl)thioureido]benzoate
-
ethyl 4-[3-(2-fluorobenzoyl)thioureido]benzoate
-
ethyl 4-[3-(3,4-dimethoxybenzoyl)thioureido]benzoate
-
ethyl 4-[3-(3-chlorobenzoyl)thioureido]benzoate
-
ethyl 4-[3-(3-methoxybenzoyl)thioureido]benzoate
-
ethyl 4-[3-(3-methylbenzoyl)thioureido]benzoate
-
ethyl 4-[3-(4-methoxybenzoyl)thioureido]benzoate
-
ethyl 4-[3-(4-methylbenzoyl)thioureido]benzoate
-
feralolide
0.5 mM, 30°C, pH 6.8, 88.7% inhibition
feroxidin
0.5 mM, 30°C, pH 6.8, 91.3% inhibition
gallacetophenone
-
0.4 mg/ml, 38% inhibition
Hpn protein
-
synthesis and purifcation of the 7 kDa protein, the synthetic nickel-binding histidine-rich protein designated Hpn is capable of abrogating urease activity of live Heicobacter pylori in liquid cultures due to inhibition of nickel uptake into cells
-
hydroxy[3-(5-[4-[(4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)(4-hydroxy-2-oxo-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]anilino]-1,3,4-thiadiazol-2-yl)phenyl]oxoammonium
-
iodoacetamide
-
phosphate protects wild-type enzyme from inactivation, does not affect inactivation of C319S urease
L-ascorbic acid
-
in an unbuffered system L-ascorbic acid inactivates urease in a biphasic manner by denaturation brought about by ascorbic acid-lowered pH. In a buffered system neither ascorbic acid nor dehydroascorbic acid themselves are inhibitors of urease
L-glutamine
-
50 mM, 14% inhibition
L-glutamyl-5-hydroxamate
-
50 mM, 34% inhibition
lyciumaside
0.5 mM, 30°C, pH 6.8, 83.5% inhibition
mercaptoethylamine
-
inactivates enzyme irreversibly
methyl (7E)-7-[4,4-dimethyl-3-(3-methylisoxazol-5-yl)-2,6-dioxocyclohexyl]-7-(ethoxyimino)heptanoate
-
chelator of the nickel atom in enzyme metallocenter
methyl 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxylate
methyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-amino-4-methylthiophene-3-carboxylate
methyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
methyl 2-amino-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate
methyl 2-[(methoxycarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[bis(chlorocarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(chloromethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(chloromethoxy)carbonyl]amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
methyl 2-[[(dichloromethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(methylsulfanyl)carbonothioyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 3-(4-[[(3-methoxy-3-oxopropyl)amino]methyl]piperidin-1-yl)propanoate
-
50% inhibition at 0.019 mM
methyl 5-[(1E)-N-(allyloxy)butanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl 5-[(1E)-N-ethoxybutanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl 5-[(1E)-N-ethoxyethanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl[(methylamino)methyl]phosphinic acid
N'-(2,3-dichlorobenzoyl)-3,4,5-trimethoxybenzohydrazide
-
N'-(2,4-dichlorobenzoyl)pyridine-3-carbohydrazide
-
N'-(2-bromobenzylidene)-2-(4-nitrophenoxy)acetohydrazide
-
-
N'-(2-ethoxybenzoyl)pyridine-3-carbohydrazide
-
N'-(3-chlorobenzoyl)pyridine-3-carbohydrazide
-
N'-(3-methylbenzoyl)pyridine-3-carbohydrazide
-
N'-(4-chlorobenzoyl)pyridine-3-carbohydrazide
-
N'-(4-methoxybenzoyl)-3,5-dimethylbenzohydrazide
-
-
N'-(4-methylbenzoyl)pyridine-3-carbohydrazide
-
N'-(4-nitrobenzylidene)-2-(4-nitrophenoxy)acetohydrazide
-
-
N'-benzoyl-2,3-dichlorobenzohydrazide
-
N'-benzoyl-2,4-dichlorobenzohydrazide
-
N'-benzoyl-3-chlorobenzohydrazide
-
N'-benzoyl-3-methylbenzohydrazide
-
N'-benzoyl-4-chlorobenzohydrazide
-
N'-benzoyl-4-methoxybenzohydrazide
-
N'-benzoyl-4-methylbenzohydrazide
-
N'-benzoylbenzohydrazide
-
N'-benzoylpyridine-3-carbohydrazide
-
N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]-benzo-hydrazide
13% inhibition at 0.01 mM
N-(1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(2,3-dimethylphenyl)-5-phenyl-1,3,4-thiadiazol-2-amine
-
-
N-(2,4-dichlorophenyl)-N'-(3,4-dimethylphenyl)thiourea
-
N-(2,4-dichlorophenyl)-N'-(3,5-dimethylphenyl)thiourea
-
N-(2,4-dichlorophenyl)-N'-(4-ethylphenyl)thiourea
-
N-(2,4-difluorophenyl)-N'-(2-iodophenyl)thiourea
-
N-(2,4-difluorophenyl)-N'-(3,4-dimethylphenyl)thiourea
-
N-(2,4-difluorophenyl)-N'-(3,5-dimethylphenyl)thiourea
-
N-(2,4-difluorophenyl)-N'-(4-iodophenyl)thiourea
-
N-(2,4-dimethylphenyl)-5-(3-nitrophenyl)-1,3,4-thiadiazol-2-amine
-
-
N-(2,5-dimethylphenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(2,5-dimethylphenyl)-N'-[3-(trifluoromethyl)phenyl]thiourea
-
N-(2-bromophenyl)-N'-(4-ethylphenyl)thiourea
-
N-(2-bromophenyl)-N'-(5-chloro-2,4-dimethoxyphenyl)thiourea
-
N-(2-bromophenyl)-N'-[2-hydroperoxy-5-(trifluoromethyl)phenyl]thiourea
-
N-(2-bromophenyl)-N'-[3-(methylsulfanyl)phenyl]thiourea
-
N-(2-chloro-4,6-dimethoxyphenyl)-N'-(3-chlorophenyl)thiourea
-
N-(2-chloro-4,6-dimethoxyphenyl)-N'-[3-(trifluoromethyl)phenyl]thiourea
-
N-(2-iodophenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(2-methoxy-4-nitrophenyl)phosphoric triamide
-
-
N-(2-nitrophenyl)phosphoric triamide
-
-
N-(2-phenylethyl)phosphoric triamide
-
-
N-(2-phenylethyl)phosphorothioic triamide
-
-
N-(3,4-dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]thiourea
-
N-(3,4-dimethylphenyl)-N'-[2-hydroperoxy-5-(trifluoromethyl)phenyl]thiourea
-
N-(3,4-dimethylphenyl)-N'-[3-(trifluoromethyl)phenyl]thiourea
-
N-(3,5-dimethylphenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(3-chlorophenyl)-N'-(3-nitrophenyl)thiourea
-
N-(3-chlorophenyl)-N'-(4-methoxyphenyl)thiourea
-
-
N-(3-chlorophenyl)-N'-[2-methoxy-5-(trifluoromethyl)phenyl]thiourea
-
N-(3-methoxyphenyl)-N'-(3-nitrophenyl)thiourea
-
N-(3-methoxyphenyl)phosphoric triamide
-
-
N-(3-methylpyridin-2-yl)phosphorothioic triamide
-
-
N-(3-morpholin-2-ylpropyl)phosphoric triamide
-
-
N-(3-nitropyridin-2-yl)phosphoric triamide
-
-
N-(4-bromophenyl)-N'-(2,4-difluorophenyl)thiourea
-
N-(4-bromophenyl)-N'-(3-chlorophenyl)thiourea
-
N-(4-bromophenyl)-N'-(3-fluorophenyl)thiourea
-
N-(4-bromophenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(4-chlorophenyl)-N'-[2-(trifluoromethyl)phenyl]thiourea
-
N-(4-cyclohexylphenyl)phosphoric triamide
-
-
N-(4-ethylphenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(4-ethylphenyl)-N'-[3-(trifluoromethyl)phenyl]thiourea
-
N-(4-fluoro-3-nitrophenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(4-iodophenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(4-iodophenyl)-N'-[3-(trifluoromethyl)phenyl]thiourea
-
N-(4-methoxy-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(4-methyl-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(4-methyl-2-nitrophenyl)phosphoric triamide
-
-
N-(4-nitrophenyl)phosphoric triamide
-
-
N-(4-phenoxyphenyl)phosphoric triamide
-
-
N-(5-chloro-2,4-dimethoxyphenyl)-N'-(3-methoxyphenyl)thiourea
-
N-(5-chloro-2,4-dimethoxyphenyl)-N'-[2-(trifluoromethyl)phenyl]thiourea
-
N-(5-chloro-2-methylphenyl)-N'-(3,4-dichlorophenyl)thiourea
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(6-fluoro-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(benzylcarbamothioyl)-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-(N'-benzyloxycarbonylglycyl)aminomethyl(P-methyl)phosphinothioic acid
N-1,3-benzothiazol-2-ylphosphoric triamide
-
-
N-1,3-benzothiazol-2-ylphosphorothioic triamide
-
-
N-adamant-1-ylphosphoric triamide
-
-
N-benzyloxycarbonylaminomethyl(P-methyl)phosphinic acid
N-dimethyl-S-methyl-L-cysteine
N-ethylmaleimide
-
irreversible inactivation
N-glycyl-aminomethyl(P-methyl)phosphinic acid
N-n-butylphosphoric triamide
-
-
N-n-butylthiophosphoric triamide
-
-
N-naphthalen-1-ylphosphoric triamide
-
-
N-phenylphosphoric triamide
-
-
N-[(2,3-dichlorophenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[(2,4-dinitrophenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[(3,5-dinitrophenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[(4-bromophenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[(4-chlorophenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[(4-methoxyphenyl)carbamothioyl]-2-[4-(2-methylpropyl)phenyl]propanamide
-
N-[2-(4-fluorophenyl)ethyl]phosphoric triamide
-
-
N-[2-(difluoromethoxy)phenyl]phosphoric triamide
-
-
N-[2-(trifluoromethoxy)phenyl]phosphoric triamide
-
-
N-[3-(methylsulfanyl)phenyl]-N'-[2-(trifluoromethyl)phenyl]thiourea
-
N-[4-(benzyloxy)phenyl]phosphoric triamide
-
-
N-[[hydroxy(methyl)phosphoryl]methyl]-L-phenylalaninamide
N-[[hydroxy(methyl)phosphoryl]methyl]-L-serinamide
N-[[hydroxy(methyl)phosphoryl]methyl]-L-valinamide
N2-[(benzyloxy)carbonyl]-N-[[hydroxy(methyl)phosphoryl]methyl]glycinamide
O-benzyl-N-[[hydroxy(methyl)phosphoryl]methyl]-L-serinamide
O-[4-(benzyloxy)phenyl] diamidothiophosphate
-
-
oxovanadium complex [VOL(AHA)]
-
reaction of N'-(3-bromo-2-hydroxybenzylidene)-4-methoxybenzohydrazide and acetohydroxamic acid with VO(acac)2 in methanol gives the complex [VOL(AHA)]. The benzohydrazone ligand, in its dianionic form, coordinates to V atom through the phenolate oxygen, imino nitrogen and enolate oxygen. The acetohydroxamic acid coordinates to V atom through the carbonyl oxygen and deprotonated hydroxyl oxygen. The V atom is in octahedral coordination. The percent inhibition at concentration of 0.1 mM/l on Helicobacter pylori urease is 78% for the oxovanadium complex
p-chloromercuribenzene sulfonate
-
0.1 mM, complete inhibition
Pb2+
-
inhibitory effect of heavy metals over immobilized enzyme decreases in the order Cu2+, Cd2+, Zn2+, Ni2+, Pb2+
PCMB
-
0.1 mM, complete loss of activity
peptides
-
TFLPQPRCSALLRYLSEDGVIVPS and YDFYWW, no inhibition of the enzyme from Bacillus pasteurii and Canavalia ensiformis
phenylphosphoramidate
-
-
Phenylurea
-
weak non-competitive
psi-tectorigenin
-
0.4 mg/ml, 36% inhibition
quercetin-4'-O-beta-D-glucopyranoside
-
-
Selenourea
-
50 mM, 80% inhibition
sulfite
competitive inhibitor. The structure of the urease-sulfite complex, determined at 1.65 A resolution, shows the inhibitor bound to the dinuclear Ni(II) center of urease in a tridentate mode involving bonds between the two Ni(II) ions in the active site and all three oxygen atoms of the inhibitor
tetrachloro-o-benzoquinone
-
no recovery of urease activity bound in the urease-inhibitor complex after dilution or addition of dithiothreitol
tetrachloro-p-benzoquinone
-
-
tetracosyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
triphenylbismuth difluoride
-
first-order rate constant for inactivation 0.00158 per s
tris(2,4,6-trimethylphenyl)bismuth
-
first-order rate constant for inactivation 0.0027 per s
tris(4-fluorophenyl)bismuth dichloride
-
first-order rate constant for inactivation 0.00158 per s
tris(4-fluorophenyl)bismuth difluoride
-
first-order rate constant for inactivation 0.00259 per s
tris(4-methylphenyl)bismuth dichloride
-
first-order rate constant for inactivation 0.00259 per s
[(acetylamino)methyl]methylphosphinic acid
[(acetylamino)methyl]phosphonic acid
-
-
[(benzylamino)methyl]methylphosphinic acid
[(dimethylamino)methyl]methylphosphinic acid
[(dimethylamino)methyl]phosphonic acid
[(methylamino)methyl]phosphonic acid
[5-[(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl](phenyl)methanol
-
-
[5-[(4-nitrophenyl)amino]-1,3,4-oxadiazol-2-yl](phenyl)methanol
-
-
[[benzyl(methyl)amino]methyl]phosphonic acid
-
-
(2S)-2-(dimethylamino)-3-(ethylthio)propan-1-ol

-
noncompetitive, 50% inhibition at 0.040 mM
(2S)-2-(dimethylamino)-3-(ethylthio)propan-1-ol
-
noncompetitive, 50% inhibition at 0.029 mM
(2S)-2-(dimethylamino)-3-ethoxypropane-1-thiol

-
noncompetitive, 50% inhibition at 0.100 mM
(2S)-2-(dimethylamino)-3-ethoxypropane-1-thiol
-
noncompetitive, 50% inhibition at 0.031 mM
(2S)-2-(dimethylamino)-3-ethoxypropane-1-thiol
-
noncompetitive, 50% inhibition at 0.020 mM
(2S)-2-(dimethylamino)-3-mercaptopropan-1-ol

-
noncompetitive, 50% inhibition at 0.022 mM
(2S)-2-(dimethylamino)-3-mercaptopropan-1-ol
-
noncompetitive, 50% inhibition at 0.025 mM
(2S)-2-(dimethylamino)-3-methoxypropane-1-thiol

-
noncompetitive, 50% inhibition at 0.035 mM
(2S)-2-(dimethylamino)-3-methoxypropane-1-thiol
-
noncompetitive, 50% inhibition at 0.036 mM
(aminomethyl)phosphonic acid

-
-
(aminomethyl)phosphonic acid
-
-
(R)-4-methoxydalbergione

-
50% inhibition at 0.067 mM, isolated from roots of Ranunculus repens
(R)-4-methoxydalbergione
-
50% inhibition at 0.059 mM, isolated from roots of Ranunculus repens
(R)-dalbergiophenol

-
50% inhibition at 0.035 mM, isolated from roots of Ranunculus repens
(R)-dalbergiophenol
-
50% inhibition at 0.025 mM, isolated from roots of Ranunculus repens
([[(benzyloxy)carbonyl]amino]methyl)methylphosphinothioic O-acid

-
-
([[(benzyloxy)carbonyl]amino]methyl)methylphosphinothioic O-acid
-
-
2,2'-bi-1,3,4-oxadiazole-5,5'(4H,4'H)-dithione

-
pH 8.2, IC50: 0.133 mM
2,2'-bi-1,3,4-oxadiazole-5,5'(4H,4'H)-dithione
-
pH 8.2, IC50: below 0.125 mM
2,2'-bi-1,3,4-oxadiazole-5,5'(4H,4'H)-dithione
-
-
2,2'-bi-1,3,4-thiadiazole-5,5'(4H,4'H)-dithione

-
pH 8.2, IC50: 0.5 mM
2,2'-bi-1,3,4-thiadiazole-5,5'(4H,4'H)-dithione
-
-
2-mercaptoethanol

-
-
3,4,5-Trihydroxybenzoate

-
50% inhibition at 0.032 mM
3,4,5-Trihydroxybenzoate
-
50% inhibition at 0.022 mM
4-(4-benzoyl-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)phenyl benzoate

-
pH 8.2, IC50: 0.234 mM
4-(4-benzoyl-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)phenyl benzoate
-
-
4-amino-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

-
pH 8.2, IC50: below 0.125 mM
4-amino-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-amino-5-pyridin-4-yl-2,4-dihydro-3H-1,2,4-triazole-3-thione

-
pH 8.2, IC50: 0.163 mM
4-amino-5-pyridin-4-yl-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-bromophenylboronic acid

-
competitive
4-bromophenylboronic acid
-
competitive inhibition
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)-3-phenylprop-2-en-1-yl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)-3-phenylprop-2-en-1-yl]-2H-chromen-2-one
-
competitive inhibition
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)but-2-en-1-yl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)but-2-en-1-yl]-2H-chromen-2-one
-
uncompetitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-indol-3-yl)methyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-indol-3-yl)methyl]-2H-chromen-2-one
-
competitive inhibition; uncompetitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-pyrrol-3-yl)methyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-pyrrol-3-yl)methyl]-2H-chromen-2-one
-
uncompetitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(3-methoxyphenyl)methyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(3-methoxyphenyl)methyl]-2H-chromen-2-one
-
competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(pyridin-4-yl)methyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(pyridin-4-yl)methyl]-2H-chromen-2-one
-
noncompetitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-2H-chromen-2-one
-
competitive inhibition, enzyme-ligand interaction analysis, structure, overview
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)ethyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)ethyl]-2H-chromen-2-one
-
uncompetitive inhibition, enzyme-ligand interaction analysis, structure, overview
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)pentyl]-2H-chromen-2-one

competitive inhibition
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)pentyl]-2H-chromen-2-one
-
competitive inhibition
5-(1-naphthyl)-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.214 mM
5-(1-naphthyl)-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: below 0.125 mM
5-(1-naphthyl)-1,3,4-oxadiazole-2(3H)-thione
-
-
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: below 0.125 mM
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
-
-
5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.5 mM
5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
-
-
5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.95 mM
5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.25 mM
5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
-
-
5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione

-
pH 8.2, IC50: below 0.125 mM
5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
-
-
5-benzyl-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: below 0.125 mM
5-benzyl-1,3,4-oxadiazole-2(3H)-thione
-
-
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.124 mM
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.125 mM
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
-
-
5-phenyl-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: below 0.125 mM
5-phenyl-1,3,4-oxadiazole-2(3H)-thione
-
-
5-phenyl-1,3,4-thiadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.29 mM
5-phenyl-1,3,4-thiadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.25 mM
5-phenyl-1,3,4-thiadiazole-2(3H)-thione
-
-
5-pyridin-4-yl-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: above 0.2 mM
5-pyridin-4-yl-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: below 0.125 mM
5-pyridin-4-yl-1,3,4-oxadiazole-2(3H)-thione
-
-
5-pyridin-4-yl-1,3,4-thiadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.124 mM
5-pyridin-4-yl-1,3,4-thiadiazole-2(3H)-thione
-
pH 8.2, IC50: below 0.125 mM
5-pyridin-4-yl-1,3,4-thiadiazole-2(3H)-thione
-
-
5-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.095 mM
5-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.5 mM
5-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)methyl]-1,3,4-thiadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.095 mM
5-[(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)methyl]-1,3,4-thiadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.5 mM
5-[(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)methyl]-1,3,4-thiadiazole-2(3H)-thione
-
-
5-[3-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl]-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.093 mM
5-[3-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl]-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: below 0.125 mM
5-[3-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione

-
pH 8.2, IC50: 0.41 mM
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
-
pH 8.2, IC50: 0.5 mM
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]oxadiazole-2-thione

-
pH 8.2, IC50: 0.244 mM
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]oxadiazole-2-thione
-
-
7'-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7-yl alpha-L-mannopyranoside

-
-
7'-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7-yl alpha-L-mannopyranoside
-
-
7'-hydroxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside

-
-
7'-hydroxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
-
-
7'-methoxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside

-
-
7'-methoxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
-
-
7-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7'-yl alpha-L-mannopyranoside

-
-
7-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7'-yl alpha-L-mannopyranoside
-
-
7-[(7-methoxy-2-oxo-2H-chromen-3-yl)oxy]-2-oxo-2H-chromen-6-yl alpha-D-glucopyranoside

-
-
7-[(7-methoxy-2-oxo-2H-chromen-3-yl)oxy]-2-oxo-2H-chromen-6-yl alpha-D-glucopyranoside
-
-
8-hydroxy-3-[(6-hydroxy-2-oxo-2H-chromen-7-yl)oxy]-2-oxo-2H-chromen-7-yl beta-D-glucopyranoside

-
-
8-hydroxy-3-[(6-hydroxy-2-oxo-2H-chromen-7-yl)oxy]-2-oxo-2H-chromen-7-yl beta-D-glucopyranoside
-
-
Acetohydroxamate

-
reversible
Acetohydroxamate
-
10 mM, 88% inhibition
Acetohydroxamate
-
10 mM, 92% inhibition
Acetohydroxamic acid

-
Acetohydroxamic acid
-
IC50: 0.005 mM
Acetohydroxamic acid
time course of enzyme inhibition, overview
Acetohydroxamic acid
-
inhibits urease activity and biofilm formation in a dose-dependent manner
Ag+

-
-
Ag+
-
time-dependent inhibition studies exhibit biphasic kinetics with heavy metal ions
aminomethyl(P-methyl)phosphinic acid

-
-
aminomethyl(P-methyl)phosphinic acid
-
-
Boric acid

-
competitive, maximal inhibition at pH 5.0, minimal inhibition at pH 10.0
Boric acid
-
competitive, pH-variation study of inhibition constant
Boric acid
competitive inhibition, which is a reversible reaction with residual activity at lower than 0.25 mM boric acid, maximal inhibition at pH 7.0-9.0 and 30°C. Boric acid binds to the active site of the enzyme
Boric acid
-
competitive inhibition
Boric acid
-
inhibits urease activity and biofilm formation in a dose-dependent manner
butylboronic acid

-
competitive
butylboronic acid
-
competitive inhibition
catechol

irreversibly inactivates the enzyme with a complex radical-based autocatalytic multistep mechanism
catechol
irreversibly inactivates the enzyme with a complex radical-based autocatalytic multistep mechanism
Cd2+

-
-
Cd2+
-
inhibitory effect of heavy metals over immobilized enzyme decreases in the order Cu2+, Cd2+, Zn2+, Ni2+, Pb2+
Co2+

-
1 mM, 39% loss of activity
Cu2+

-
-
Cu2+
-
inhibitory effect of heavy metals over immobilized enzyme decreases in the order Cu2+, Cd2+, Zn2+, Ni2+, Pb2+. Enzyme immobilized on membranes modified with NH2NH2/H2SO4, NaOH + ethylenediamine or H2O2 is most sensitive to Cu2+
Cu2+
-
1 mM, complete inactivation
Cu2+
-
time-dependent inhibition studies exhibit biphasic kinetics with heavy metal ions
EDTA

-
-
EDTA
-
5 mM, 70% inhibition
Fe2+

-
1 mM, 42% loss of activity
fluoride

-
-
fluoride
-
two fluoride anions are coordinated to the Ni(II) ions in the active site, in terminal and bridging positions. One fluoride competitively binds to the Ni(II) ion proposed to coordinate urea in the initial step of the catalytic mechanism, while another fluoride uncompetitively substitutes the Ni(II)-bridging hydroxide, blocking its nucleophilic attack on urea. Kinetic studies on the fluoride-induced inhibition of urease, mixed competitive and predominant uncompetitive mechanism that increases by increasing the pH, and a lesser competitive inhibition that increases by lowering the pH, overview
Hg2+

-
-
Hg2+
-
1 mM, complete inactivation
Hg2+
-
time-dependent inhibition studies exhibit biphasic kinetics with heavy metal ions
hydroxamic acid

hydroxamic acids are strong inhibitors of urease due to their chelating ability. They bind the Ni(II) centers present in the active site of urease in their anionic form via the (O,O) coordination mode. The Ni(II) centers of the urease active site are electrophilic in nature. This is responsible for appreciable charge transfer from the nucleophilic oxygen centers of the hydroxamate ligand to the Ni(II) centers when they bind in the active site. Hydroxamic acids with hydrophobic groups attached to them are more potent inhibitors of urease because they can easily penetrate the hydrophobic environment surrounding the active site. The -CONHO-x01moiety of the hydroxamic acid is also found to be absolutely necessary for chelation and inhibition of urease
hydroxamic acid
-
1.0 mM, 64% inhibition
hydroxylamine

-
50 mM 23% inhibition
hydroxylamine
-
50 mM, 31% inhibition
Hydroxyurea

-
reversible
Hydroxyurea
-
IC50: 0.1 mM